CEO Brady Todd Buys 250k Aldeyra Shares Amid 6.9% Drop – Bullish Signal for Ocular Biotech
CEO Brady Todd buys 250k Aldeyra shares amid a sharp drop—signals insider confidence, potential upside, and a focus on dry‑eye therapy.
3 minutes to read
ALDEYRA THERAPEUTICS INC
Insider Buys Aldeyra Shares Amid Institutional Sell‑Off, Signals Mixed Outlook
Insider buying shows Aldeyra’s upside potential amid volatile markets; evaluate the risk‑reward of this “buy‑the‑dip” signal.
2 minutes to read
Alfieri Michael’s Insider Buy Signals Confidence in Aldeira’s Rare‑Disorder Therapy
Alfieri Michael’s insider buy of 5,000 Aldeira shares signals confidence in its orphan‑drug pipeline, suggesting potential upside despite recent FDA setbacks.
4 minutes to read